Bayer-Broad Collaboration in Cardiovascular Disease

While a majority of cardiovascular disease can be associated with lifestyle factors such as tobacco use, diet, and level of physical activity, risk genes can influence the predisposition to cardiovascular disease, its age of onset, and its severity. In 2015, the Broad expanded its ongoing collaboration with Bayer to include cardiovascular genomics, an emerging field of cardiology that uses genomic information to characterize disease risk and identify new therapeutic targets for drug discovery. The effort combines Bayer’s expertise in cardiovascular therapeutics with Broad’s deep knowledge of genomics and biology. The goal is to leverage insights from human genetics to help create new cardiovascular therapies.